Most Read Articles
Pearl Toh, 2 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
Yesterday
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.

On-demand use of clomipramine effective, safe in men with premature ejaculation

28 Nov 2018

Use of clomipramine as an on-demand treatment of premature ejaculation is well tolerated and effective, with the results of a phase III study showing increased ejaculation time during vaginal penetration.

A total of 159 patients with premature ejaculation were randomized to receive clomipramine 15 mg (n=106) or placebo (n=53) orally for 12 weeks. Patients were instructed to take the drug around 2–6 hours prior to planned sexual intercourse. They underwent evaluations at baseline and every 4 weeks.

Treatment efficacy was evaluated using Intravaginal Ejaculation Latency Time (IELT) and Premature Ejaculation Diagnostic Tool (PEDT) scores.

After 12 weeks of treatment, the mean IELT significantly increased in the clomipramine 15 mg group than in the placebo group (intention-to-treat: 4.40±5.29 vs 2.68±2.03; p<0.05). Fold change of IELT in the per-protocol population was also significantly different between the two treatment groups, in favour of the active drug (mean: 4.66±5.64 vs 2.80±2.19; p<0.05).

Likewise, there was a significant between-group difference in PEDT scores, which were better with clomipramine vs placebo (p<0.001).

Adverse events were mild to moderate in severity. The most commonly reported were nausea (15.7 percent) and dizziness (4.9 percent).

A tricyclic antidepressant, clomipramine hydrochloride is indicated for obsessive-compulsive disorder, panic disorder and depressive disorder. The drug is said to be the most potent inhibitor of 5- hydroxytryptamine (serotonin) reuptake among antidepressants. Side effects include dry mouth, nausea, constipation, loss of appetite, fatigue and dizziness. [Int J Impot Res 2018;30:65-70]

Editor's Recommendations
Most Read Articles
Pearl Toh, 2 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
Yesterday
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.